Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of Z-215 vs Rabeprazole in Healthy Males
NCT02509923Phase 1Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azeloprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (3 cohorts), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoints: 24-Hour Intragastric pH Profile at 4 weeks, Maximum Plasma Concentration at 4 weeks and 5 more. Started Jul 2015; status: completed.
02
Drugs
azeloprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT02509923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509923.